B-type natriuretic peptide concentrations to guide treatment of patent ductus arteriosus

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 94, Issue 3, 2009, Pages

  Attridge, J T ^a,c   Kaufman, D A ^a   Lim, D S ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; INDOMETACIN;

APGAR SCORE; ARTICLE; CHRONIC LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; GESTATIONAL AGE; HUMAN; INFANT; INTESTINE PERFORATION; LIGATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NEWBORN; NEWBORN INTENSIVE CARE; PATENT DUCTUS ARTERIOSUS; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; CYCLOOXYGENASE INHIBITORS; DUCTUS ARTERIOSUS, PATENT; ECHOCARDIOGRAPHY; FEMALE; HUMANS; INDOMETHACIN; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; MALE; NATRIURETIC PEPTIDE, BRAIN; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRGINIA;

EID: 67650093212     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/adc.2008.147587     Document Type: Article

References (23)

1. Heymann MA, Rudolph AM, Silverman NH. Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. N Engl J Med 1976;295:530-533
2. Freidman WF, Hirschklau MJ, Printz MP, et al. Pharmacologic closure of patent ductus arteriosus in the premature infant. N Engl J Med 1976;295:526-529
3. Attridge JT, Clark R, Walker MW, et al. New insights into spontaneous intestinal perforation using a national data set: (1) SIP is associated with early indomethacin exposure. J Perinatol 2006;26:93-99
4. Yanagi RM, Wilson A, Newfeld EA, et al. Indomethacin treatment for symptomatic patent ductus arteriosus: a double-blind control study. Pediatrics 1981;67:647-652 (Pubitemid 11061284)
5. Gersony WM, Peckham GJ, Ellison RC, et al. Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. J Pediatr 1983;102:895-906.
6. Sperandio M, Beedgen B, Feneberg R, et al. Effectiveness and side effects of an escalating, stepwise approach to indomethacin treatment for symptomatic patent ductus arteriosus in premature infants below33 weeks of gestation. Pediatrics 2005;116:1361-1366 (Pubitemid 46056483)
7. Van Overmeire B, Van de Broek H, Van Laer P, et al. Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome. J Pediatr 2001;138:205-211 (Pubitemid 32156435)
8. LaughonMM, SimmonsMA, Bose CL. Patency of the ductus arteriosus in the premature infant: is it pathologic? Should it be treated? Curr Opin Pediatr 2004;16:146-151
9. Costello JM, Goodman DM, Green TP. A review of the natriuretic hormone system's diagnostic and therapeutic potential in critically ill children. Pediatr Crit Care Med 2006;7:308-318 (Pubitemid 44048272)
10. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-167 (Pubitemid 34764819)
11. Choi BM, Lee KH, Eun BL, et al. Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants. Pediatrics 2005;115:e255-61.
12. Flynn PA, da Graca RL, Auld PA, et al. The use of a bedside assay for plasma B-type natriuretic peptide as a biomarker in the management of patent ductus arteriosus in premature neonates. J Pediatr 2005;147:38-42. (Pubitemid 40981143)
13. Sanjeev S, Pettersen M, Lua J, et al. Role of plasma B-type natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates. J Perinatol 2005;25:709-713 (Pubitemid 41655645)
14. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-1463 (Pubitemid 41821197)
15. Hiraishi S, DiSessa TG, Jarmakani JM, et al. Two-dimensional echocardiographic assessment of left atrial size in children. Am J Cardiol 1983;52:1249-1257 (Pubitemid 14243981)
16. Attridge JT, Herman AC, Gurka MJ, et al. Discharge outcomes of extremely low birth weight infants with spontaneous intestinal perforations. J Perinatol 2006;26:49-54. (Pubitemid 43135255)
17. Chen YH, DeMets DL, Lan KKG. Increasing the sample size when the unblinded interim result is promising. Stat Med 2004;23:1023-1038 (Pubitemid 38477065)
18. Clyman RI, Chorne N. Patent ductus arteriosus: evidence for and against treatment. J Pediatr 2007;150:216-219 (Pubitemid 46328984)
19. Doust JA, Glasziou PP, Pietrzak E, et al. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med 2004;164:1978-1984 (Pubitemid 39390553)
20. Reynolds EW, Ellington JG, Vranicar M, et al. Brain-type natriuretic peptide in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatrics 2004;114:1297-1304 (Pubitemid 41647692)
21. Cannesson M, Bionda C, Gostoli B, et al. Time course and prognostic value of plasma B-type natriuretic peptide concentration in neonates undergoing the arterial switch operation. Anesth Analg 2007;104:1059-1065 (Pubitemid 46649922)
22. Kabra NS, Schmidt B, Roberts RS, et al. Neurosensory impairment after closure of patent ductus arteriosus in extremely low birth weight infants: results from the trial of indomethacin prophylaxis in preterms. J Pediatr 2007;150:229-234 (Pubitemid 46343549)
23. Laughon M, Bose CL, Clark R. Treatment strategies to prevent or close a patent ductus arteriosus in preterm infants and outcomes. J Perinatol 2007;27:164-170 (Pubitemid 46322647)